Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis.

Published in: Multiple sclerosis journal - experimental, translational and clinical (2022)

We did not identify any major safety signals among the patients who received ocrelizumab prior to conception or during the first trimester of pregnancy. Our patients appeared to have a stable disease course despite a prolonged period of treatment interruption during pregnancy.

Keyphrases

multiple sclerosis
end stage renal disease
preterm birth
newly diagnosed
ejection fraction
chronic kidney disease
pregnancy outcomes
prognostic factors
peritoneal dialysis
smoking cessation